Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Size (2024 - 2029)

Non-steroidal Anti-inflammatory Drugs Market Analysis

The Non-steroidal Anti-Inflammatory Drugs Market size is estimated at USD 26.83 billion in 2024, and is expected to reach USD 39.22 billion by 2029, growing at a CAGR of 7.89% during the forecast period (2024-2029).

The increasing burden of chronic pain and inflammatory diseases globally is expected to boost the market's growth during the forecast period, as NSAIDs are widely used in their treatment and management. In addition, investment in research and development by pharmaceutical companies to develop advanced NSAIDs is likely to contribute to market expansion.

The high prevalence of low back pain, which is expected to increase in the coming years, is anticipated to lead to a rise in the usage of NSAIDs during the forecast period. For instance, according to data published by the WHO in December 2023, projections estimate that 843 million individuals will experience low back pain by 2050, with the most significant increases expected in Africa and Asia due to their expanding populations and increasing life expectancies. This high number of low back pain cases increases the usage of NSAIDs and is expected to contribute to the growth of the market during the forecast period.

Musculoskeletal conditions such as arthritis and back pain are some of the leading contributors to disability worldwide. For instance, according to data published by the National Center for Health Statistics in February 2024, the age-adjusted prevalence of arthritis in adults aged 18 and older in the United States was reported to be 18.9% in 2022, which is significantly high. Therefore, the high burden of musculoskeletal disorders is likely to lead to a growing demand for pain management drugs such as NSAIDs, contributing to the market's growth during the forecast period.

Also, the growing awareness among the public through awareness initiatives likely increases the usage of aspirin as it is widely used in cardiovascular diseases. For instance, in February 2023, Huma Therapeutics Limited and Bayer entered a partnership to develop the Bayer aspirin heart risk assessment online tool to raise awareness of heart health and its risk factors. Hence, understanding heart health and its risk factors helps increase aspirin usage in ongoing health management. Thus, this growing awareness is expected to drive market growth due to the proper usage of NSAIDs by the public.

Therefore, the high burden of pain cases due to musculoskeletal conditions and increasing awareness are likely to drive market growth during the forecast period. However, the side effects caused by the use of NSAIDs are expected to restrain the market's growth during the forecast period.

Non-steroidal Anti-inflammatory Drugs Industry Segmentation

As per the report's scope, non-steroidal anti-inflammatory drugs (NSAIDs) are medications that reduce pain, decrease fever, prevent blood clots, and decrease inflammation in higher doses. NSAIDs inhibit enzymes in the body that produce prostaglandins, which are naturally occurring fatty acids that contribute to pain and inflammation.

The non-steroidal anti-inflammatory drugs (NSAIDs) market is segmented by route of administration, application, distribution channel, and geography. By route of administration, the market is segmented into oral, parenteral, topical, and other routes of administration. By application, the market is segmented into arthritis, migraine, ophthalmic diseases, and other applications. The other applications include fever and blood clots. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and other distribution channels. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the market size and forecasts in value (USD) for the above segments.